1. OFEV® (nintedanib) efficacy
INPULSIS® trial results for lung function
Last updated
These slides are provided by Boehringer Ingelheim for medical to medical education only.

2. Annual rate of decline in FVC
Treated set (observed cases); data are adjusted rate (SEM).
Richeldi L, et al. N Engl J Med 2014;370:2071–2082.

3. Annual rate of decline in FVC: Pooled data
Treated set (observed cases); data are adjusted rate (SEM).
Richeldi L, et al. N Engl J Med 2014;370:2071–2082.

4. Change from baseline in FVC over time: INPULSIS®-1
*Adjusted mean difference versus placebo at Week 52 based on mixed effects model for repeated measures. Richeldi L, et al. N Engl J Med 2014;370:2071–2082.

5. Change from baseline in FVC over time: INPULSIS®-2
*Adjusted mean difference versus placebo at Week 52 based on mixed effects model for repeated measures. Richeldi L, et al. N Engl J Med 2014;370:2071–2082.

6. Change from baseline in FVC over time: Pooled data
*Adjusted mean difference versus placebo at Week 52 based on mixed effects model for repeated measures. Richeldi L, et al. N Engl J Med 2014;370:2071–2082.

7. Absolute change from baseline in FVC % predicted at week 52
Richeldi L, et al. N Engl J Med 2014;370:2071–2082.

8. Annual rate of decline in FVC in subgroups by absence/presence of emphysema at baseline
Cottin V, et al. 18th International Colloquium on Lung and Airway Fibrosis 2014; Effect of Baseline Emphysema on Reduction in FVC Decline with Nintedanib in the INPULSIS™ Trials (Abstract).

9. Annual rate of decline in FVC in subgroups by FEV1/FVC ratio at baseline
Kolb M, et al. 18th International Colloquium on Lung and Airway Fibrosis 2014; Effect of FEV1/FVC Ratio on Reduction in FVC Decline with Nintedanib in the INPULSIS™ Trials (Abstract).

10. Find out more on global.OFEV.com